Sareum Holdings PLC Executive Chairman Dr. Stephen Parker talked about the company’s progress developing next-generation therapies targeting cancer and autoimmune diseases at the Proactive One2One Investor forum.
Sareum is advancing SDC-1801, a dual TYK2/JAK1 inhibitor that completed phase one trials with what Parker described as “no serious drug related events at all,” highlighting its clean safety profile and potential for once-daily dosing. The company has started a 16-week toxicology study that is expected to complete by year-end 2025, preparing the drug for phase two readiness in early 2026.
Parker also discussed SDC-1802, which is positioned as a cancer immunotherapy with a strong signal in preclinical studies. Sareum plans to initiate further preclinical work around the turn of the year.
The company regained majority control of its CHK1 inhibitor program, SRA737, after Sierra Oncology returned the asset following GSK’s acquisition. Sareum now holds a 63.5% economic interest and is evaluating options to out-license the program.
#Sareum #SDC1801 #SDC1802 #CancerTherapy #AutoimmuneDiseases #DrugDevelopment #BiotechInvesting #CHK1Inhibitor #Immunotherapy #Pharmaceuticals #ClinicalTrials #ProactiveInvestors